New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer.

Metastatic prostate cancer Prostate-specific membrane antigen Targeted radionuclide therapy

Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
13 Aug 2024
Historique:
received: 06 06 2024
accepted: 31 07 2024
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 14 8 2024
Statut: aheadofprint

Résumé

Metastatic prostate cancer is a frequent and fatal disease. Targeted radionuclide therapy (TRT) has become a readily available therapeutic option since the approval of [

Identifiants

DOI: 10.1016/j.euf.2024.07.016 PMID: 39142998
pubmed: 39142998
pii: S2405-4569(24)00154-8
doi: 10.1016/j.euf.2024.07.016
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Kévin Hébert (K)

Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France.

Paul Bodin-Cufi (P)

Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France.

Cyril Fersing (C)

Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; Institut des Biomolécules Max Mousseron, University of Montpellier, Montpellier, France.

Emmanuel Deshayes (E)

Nuclear Medicine Department, Institut Régional du Cancer de Montpellier, University of Montpellier, Montpellier, France; INSERM U1194, Institut de Recherche en Cancérologie de Montpellier, University of Montpellier, Montpellier, France. Electronic address: emmanuel.deshayes@icm.unicancer.fr.

Classifications MeSH